Morsa Images/DigitalVision via Getty ImagesInvestment action I recommended a buy rating for Progyny, Inc. (NASDAQ:PGNY) when I wrote about it in mid-March this year, as I continued to view the long-term growth outlook as attractive. Based on my current outlook and analysis, I recommend a buy rating. My key update to my thesis is that I don’t think the weakness in 1Q24 revenue is indicative of a structural long-term impairment to growth. Historical US ART cycles suggest a solid long-term growth trend, an ...